{
    "clinical_study": {
        "@rank": "48599", 
        "acronym": "RDN + AF", 
        "arm_group": [
            {
                "arm_group_label": "Cardiac ablation + renal artery ablation", 
                "arm_group_type": "Experimental", 
                "description": "Renal artery ablation with the EnligHTN\u2122 Renal Denervation System"
            }, 
            {
                "arm_group_label": "Cardiac ablation", 
                "arm_group_type": "Active Comparator", 
                "description": "Cardiac ablation"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this post market clinical investigation is to complete preliminary evaluation\n      on whether or not concomitant renal denervation with the EnligHTN\u2122 Renal Denervation System\n      and cardiac ablation will result in improved outcomes as compared to ablation alone in\n      patients with uncontrolled hypertension being treated for Atrial Fibrillation"
        }, 
        "brief_title": "A Feasibility Study to Evaluate the Effect of Concomitant Renal Denervation and Cardiac Ablation on AF Recurrence", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Persistent Atrial Fibrillation", 
            "Paroxysmal Atrial Fibrillation", 
            "Hypertension", 
            "Renal Denervation", 
            "Cardiac Ablation"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Atrial Fibrillation", 
                "Hypertension", 
                "Recurrence"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject is \u2265 18 years of age at time of consent\n\n          -  Subject must be able and willing to provide written informed consent\n\n          -  Subject must be able and willing to comply with the required follow-up schedule\n\n          -  Subject is a candidate for catheter ablation for the treatment of paroxysmal or\n             persistent atrial fibrillation as per the hospital standard of care\n\n          -  Subject has office Systolic Blood Pressure \u2265 140 mmHg at baseline visit\n\n          -  Subject has a daytime mean Systolic Ambulatory Blood Pressure > 135 mmHg within 90\n             days prior to procedure\n\n          -  Subject has established hypertension (diagnosed \u226512 month prior to baseline) and is\n             taking >3 anti-hypertensive medications, including 1 diuretic\n\n          -  Subject has been on a stable unchanged anti-hypertensive medication regimen for a\n             minimum of 4 weeks prior to the ablation procedure\n\n        Exclusion Criteria:\n\n          -  Subject has long standing atrial fibrillation\n\n          -  Subject has had a previous ablation for atrial fibrillation\n\n          -  Subject has had a previous renal denervation procedure\n\n          -  Subject has had a CABG procedure within the last 180 days (six months)\n\n          -  Subject has a left atrial thrombus\n\n          -  Subject has a contraindication to anticoagulation (i.e. heparin or warfarin)\n\n          -  Subject has unstable angina\n\n          -  Subject has had a myocardial infarction within the previous two months\n\n          -  Subject has a left ventricular ejection fraction (LVEF) <40% as determined by\n             pre-procedure TTE\n\n          -  Subject has significant renovascular abnormalities such as renal  artery stenosis >\n             30%\n\n          -  Subject has undergone prior renal angioplasty, renal denervation,  indwelling renal\n             stents, and/or abdominal aortic stent grafts\n\n          -  Subject has hemodynamically significant valvular heart disease as determined by study\n             investigator\n\n          -  Subject has a life expectancy less than 12 months, as determined by the study\n             investigator\n\n          -  Subject is participating in another clinical study which has the potential to impact\n             his/her  hypertension or atrial fibrillation management\n             (pharmaceutical/device/homeopathic)\n\n          -  Subject is pregnant, nursing, or of childbearing potential and is not using adequate\n             contraceptive methods\n\n          -  Subject has active systemic infection\n\n          -  Subject has renal arteries < 4 mm in diameter\n\n          -  Subject has an estimated GFR <45 mL/min per 1.73 m2 using the Modification of Diet in\n             Renal Disease (MDRD) formula\n\n          -  Subject had a renal transplant or is awaiting a renal transplant\n\n          -  Subject has blood clotting or bleeding abnormalities\n\n          -  Subject has secondary arterial hypertension"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01907828", 
            "org_study_id": "SJM-CIP-0009"
        }, 
        "intervention": [
            {
                "arm_group_label": "Cardiac ablation + renal artery ablation", 
                "intervention_name": "Renal Artery Ablation Catheter", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": [
                    "Cardiac ablation + renal artery ablation", 
                    "Cardiac ablation"
                ], 
                "intervention_name": "Cardiac Ablation", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 21, 2014", 
        "location": [
            {
                "contact": {
                    "email": "hzd-rhythmologie@herzzentrum-dresden.com", 
                    "last_name": "Christopher Piorkowski, MD", 
                    "phone": "+49 351 450-1900"
                }, 
                "facility": {
                    "address": {
                        "city": "Dresden", 
                        "country": "Germany", 
                        "zip": "01307"
                    }, 
                    "name": "Herzzentrum Dresden GmbH Universit\u00e4tsklinik"
                }, 
                "investigator": {
                    "last_name": "Christopher Piorkowski, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "katja.palm@med.uni-leipzig.de", 
                    "last_name": "Katja Palm"
                }, 
                "facility": {
                    "address": {
                        "city": "Leipzig", 
                        "country": "Germany", 
                        "zip": "04289"
                    }, 
                    "name": "Herzzentrum Leipzig GmbH"
                }, 
                "investigator": {
                    "last_name": "Gerhard Hindricks, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Feasibility Study to Evaluate the Effect of Concomitant Renal Denervation and Cardiac Ablation on AF Recurrence", 
        "overall_contact": {
            "email": "acampbell2@sjm.com", 
            "last_name": "Andrew Campbell"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Ethics Commission"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Freedom from atrial fibrillation in patients with hypertension", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01907828"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Major adverse cardiac events", 
                "safety_issue": "Yes", 
                "time_frame": "7 days, 6 months, and 12 months post procedure"
            }, 
            {
                "measure": "Percent of patients who experience a procedural related event", 
                "safety_issue": "Yes", 
                "time_frame": "30 days post procedure"
            }, 
            {
                "measure": "Assessment of renovascular safety as measured by new renal artery stenosis or aneurysm at the site of ablation", 
                "safety_issue": "Yes", 
                "time_frame": "6 months, 12 months"
            }, 
            {
                "measure": "Renal function change based on eGFR (renal denervation group only)", 
                "safety_issue": "Yes", 
                "time_frame": "6 months,12 months"
            }, 
            {
                "measure": "Recurrence of AF based on electrocardiographic data up to 2 years following the initial cardiac ablation procedure.", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Percentage of subjects achieving office Systolic Blood Pressure < 140", 
                "safety_issue": "No", 
                "time_frame": "6 months post procedure"
            }, 
            {
                "measure": "Change in Office and Ambulatory Blood Pressure parameters", 
                "safety_issue": "No", 
                "time_frame": "6 month, 12 month, 24 month post procedure"
            }
        ], 
        "source": "St. Jude Medical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "St. Jude Medical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}